Biểu đồ giá cổ phiếu VRDN
VRDN Tài chính
Viridian Therapeutics Inc
$17.24
-2.54%
$-0.45
Khi đóng cửa: May 22, 16:00:00 GMT-4
$17.58
1.97%
$0.33
Phiên sau giờ: May 22, 20:00:00 GMT-4
Quay lại
Viridian Therapeutics Inc (VRDN) Tài chính
Thống kê chính
Giá đóng cửa trước
$17.69
Giá mở cửa
$17.72
Phạm vi ngày
$17.16 - $18.2
Phạm vi 52 tuần
$13.18 - $34.29
Khối lượng
2.7M
Khối lượng trung bình
2.3M
Tỷ suất cổ tức
--
EPS (TTM)
-3.96
Vốn hóa thị trường
$1.9B
VRDN là gì?
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
